T1	Participants 119 160	native coronary lesions 12-month outcomes
T2	Participants 243 333	Zotarolimus-Eluting and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease
T3	Participants 900 1022	single-blind, controlled trial comparing outcomes of patients with single de novo coronary lesions treated with ZES or PES
T4	Participants 1109 1181	cardiac death, myocardial infarction, or target vessel revascularization
T5	Participants 1197 1278	a total of 1,548 patients assigned to ZES (n = 773) or PES (n = 775), at 9 months
T6	Participants 1425 1471	periprocedural myocardial infarctions with ZES
T7	Participants 1568 1677	groups in rates of cardiac death, myocardial infarction, target vessel revascularization, or stent thrombosis
T8	Participants 1937 1984	patients without planned angiographic follow-up
T9	Participants 2123 2183	simple and medium complexity single de novo coronary lesions
